Market Place
Sourcing Support
NiKang Therapeutics Presents NKT3964 PROTAC Degrader For Cancer
24 Oct 2024 //
BUSINESSWIRE
NiKang To Present NKT2152 Data For Renal Cell Carcinoma At ESMO
09 Sep 2024 //
BUSINESSWIRE
NiKang Doses First CDK2 Inhibitor NKT3447 Patient
15 Apr 2024 //
BUSINESSWIRE
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
04 Jan 2024 //
BUSINESSWIRE
NiKang Enters into Clinical Trial Collaboration Agreement to Evaluate NKT2152
08 Dec 2023 //
BUSINESSWIRE
NiKang Therapeutics appoints Anne E. Borgman to company’s Board of Directors
20 Jan 2023 //
PHARMABIZ
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
18 Jan 2023 //
BUSINESSWIRE
NiKang Tx, Hansoh Pharma Announce Strategic Collaboration and License Agreement
03 May 2022 //
BUSINESSWIRE
NiKang Tx Shows PC Data on NKT2152’s Potential in ccRCC & Solid Tumors
08 Apr 2022 //
BUSINESSWIRE
NiKang, AVEO Oncology Announce a Clinical Trial Collaboration & Supply Agreement
05 Jan 2022 //
BUSINESSWIRE
NiKang Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152
15 Nov 2021 //
BUSINESSWIRE
NiKang Begins Dosing in Phase 1/2 Study Evaluating NKT2152 for Advanced ccRCC
15 Nov 2021 //
BUSINESSWIRE
NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer
10 Jun 2021 //
BUSINESSWIRE
NiKang Therapeutics secures $200m in Series C funding
27 May 2021 //
PHARMACEUTICAL-TECHNOLOGY
NiKang Therapeutics Announces Completion of $200 Million Series C Financing
26 May 2021 //
BUSINESSWIRE
Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C
26 May 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.